AMENDED AND RESTATED STOCK PURCHASE AGREEMENT
Agreement dated March 24, 2000, by and among ▇▇▇▇▇▇.▇▇▇ Inc., a Delaware
Corporation with its principal executive offices located at ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇, ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ (hereinafter referred to as
"AcuBid"), AcuBid Acquisition Corporation, a Delaware corporation wholly owned
by AcuBid (hereinafter referred to as "Acquisition Corp."), PT Jaring Data
Interaktif, an Indonesian corporation with its principal offices located at
Wisma Indovision, Mezzanine Floor, ▇▇. ▇▇▇▇ ▇▇▇▇▇▇▇ ▇/▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇
▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇ (hereinafter referred to as "JDI") and Adisatrya ▇▇▇▇▇ ▇▇▇▇▇▇▇
(hereinafter referred to as "Seller").
W I T N E S S E T H:
- - - - - - - - - -
WHEREAS, Seller is the owner of at least ninety percent (90%) of all of
the outstanding capital stock of JDI, and
WHEREAS, Acquisition Corp. desires to purchase from Seller, and Seller
desires to sell to Acquisition Corp., ninety percent (90%) of all of the issued
and outstanding shares of JDI for consideration all upon and subject to the
terms and conditions hereinafter set forth;
NOW, THEREFORE, in consideration of the foregoing and of the mutual
promises, covenants, representations, warranties and conditions herein
contained, the parties hereto agree as follows:
ARTICLE I -- SALE AND PURCHASE OF CAPITAL STOCK.
------------------------------------------------
Upon the terms and subject to the conditions set forth in this
Agreement, the Seller agrees to sell, assign, transfer and deliver to
Acquisition Corp. and Acquisition Corp. agrees to purchase from the Seller, on
the Closing Date (as hereinafter defined) ninety percent (90%) of the issued and
outstanding shares of JDI ("JDI Stock").
1
ARTICLE II -- PURCHASE PRICE AND PAYMENT.
-----------------------------------------
2.1 Subject to adjustments as provided in paragraph 3 below, the
aggregate purchase price to be paid to Seller for all the shares of JDI Stock to
be purchased by Acquisition Corp. hereunder shall be 44,000,000 shares of AcuBid
Common Stock, $.001 par value ("AcuBid Common Stock").
ARTICLE III -- ADJUSTMENTS OF PURCHASE PRICE.
---------------------------------------------
3.1 Seller contemplates arranging for the ▇▇▇▇▇ ▇. ▇▇▇▇▇▇ Trust
("Zilkha"), to purchase 5,000,000 shares (the "Additional Shares") of AcuBid
Common Stock at $2.00 per share, for an aggregate cash purchase price of
$10,000,000, at and subject to the Closing. AcuBid agrees to issue and sell the
Additional Shares to Zilkha at such price subject to Zilkha making the same
investment representations required of Seller under Section 4.20 of this
Agreement. This Agreement is made in part for the benefit of Zilkha, and Zilkha
shall be entitled to all rights, remedies and other benefits under this
Agreement to which Seller is entitled, on a pro rata basis in accordance with
the number of shares of AcuBid Common Stock issued or to be issued to each. Such
rights, remedies and other benefits shall include, without limitation, all
representations, warranties, covenants and agreements of AcuBid and Acquisition
Corp. hereunder and all registration rights granted to Seller under this
Agreement. The parties acknowledge that after the Closing, Zilkha may transfer
some or all of the Additional Shares to the children or grandchildren of ▇▇▇▇▇
▇. ▇▇▇▇▇, or to trusts for their benefit, subject to such transferees making the
same investment representations required of Seller under Section 4.20 of this
Agreement.
ARTICLE IV -- REPRESENTATIONS AND WARRANTIES OF SELLER
------------------------------------------------------
Seller hereby represents and warrants to AcuBid and Acquisition Corp.
as follows:
2
4.1 CORPORATE ORGANIZATION; GOOD STANDING JDI is a corporation duly
organized, validly existing and in good standing under the laws of Indonesia,
and has the corporate power and authority to carry on its business as presently
conducted. The copies of JDI's Certificate of Incorporation and By-Laws, and all
amendments thereto, which have heretofore been delivered to AcuBid and
Acquisition Corp. are complete and correct as of the date hereof. JDI is duly
qualified to do business and is in good standing in Indonesia.
4.2 CAPITALIZATION As of the date hereof, the authorized capital stock
of JDI consists of 20,000,000,000 shares of Common Stock, par value 25
Indonesian Rupiahs per share, of which 200,000,000 shares are issued and
outstanding and owned of record and beneficially by the JDI Shareholders. There
are no outstanding options, warrants, or other rights to subscribe for or
purchase any capital stock of JDI or securities convertible into or exchangeable
for capital stock of JDI.
4.3 SUBSIDIARIES JDI does not own, directly or indirectly, any shares
of capital stock of any corporation other than PT. Media Lintas Antarbuana ("PT.
MLA"), which validly exists and is in good standing under the laws of Indonesia,
has the corporate power and authority to carry on its business as presently
conducted. The JDI Schedule attached hereto and made a part hereof sets forth an
accurate description of the capitalization of PT. MLA, and the number of shares
and percentage of outstanding shares of each class of its capital stock owned
(directly or indirectly) by JDI. The shares of capital stock of PT. MLA stated
therein to be owned by JDI are so owned free and clear of all liens, options,
charges or encumbrances of any kind, and are validly issued fully paid and
non-assessable, and there are no outstanding options or agreements of any kind
relating to the issuance to any person of any shares of capital stock or
securities convertible into or exchange for capital stock of PT. MLA.
3
4.4 FINANCIAL STATEMENTS Seller has furnished AcuBid and Acquisition
Corp. with (i) the Consolidated Balance Sheet of JDI as at December 31, 1999,
and the related Consolidated Statements of Operations Changes in Stockholder
Equity and Cash Flows from inception (February 25, 1999) to December 31, 1999,
including the notes thereto, all certified by ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇, independent
certified public accountants. All such financial statements have been prepared
in accordance with generally accepted accounting principals consistently applied
and fairly present the financial position, results of operations, additional
paid in capital and retained earnings and changes in financial position of JDI
at such dates and for the period indicated. The Balance Sheet as at December 31,
1999 is hereinafter referred to as the "JDI Balance Sheet" and the date thereof
as the "JDI Balance Sheet Date".
4.5 ABSENCE OF CERTAIN EVENTS Since the JDI Balance Sheet Date there
has not been any:
a. Material adverse changes in the business, operations, or
financial condition of JDI or any physical damage, destruction or loss
(whether or not covered by insurance) materially adversely affecting
the property or business of JDI;
b. Declaration, setting aside or payment of dividends or other
distribution by JDI in respect of its capital stock, or any redemption,
purchase or other acquisition of any such stock;
c. Issuance, transfer, sale of, or contract to sell, any
shares, warrants, options or other corporate securities or obligations
convertible into shares of JDI capital stock, except as already
acknowledged by AcuBid and Acquisition Corp.;
d. Indebtedness incurred by JDI for borrowed money except for
short term borrowings incurred in the ordinary course of business,
except as already acknowledged by AcuBid and Acquisition Corp.;
e. Mortgage, pledge or subjection to lien of any of the
material assets or properties of JDI, except in the ordinary course of
business; or
f. Labor strike or other occurrence, event or condition of any
similar character which materially adversely affects the business,
operations or financial condition of JDI.
4
4.6 LIABILITIES As of the date hereof, there are no material
liabilities, debt or obligations of JDI, of the type normally shown on a balance
sheet (including notes thereto) in accordance with generally accepted accounting
principles, whether accrued, absolute, contingent or otherwise and whether due
or to become due, including, but not limited to, liabilities or obligations on
account of taxes or other government charges, other than (i) liabilities
disclosed in the JDI Balance Sheet or in the contracts or agreements referred to
therein, and (ii) liabilities incurred in the ordinary course of business since
the JDI Balance Sheet Date none of which has been materially adverse to the
business, operations or financial condition of JDI.
4.7 TAX RETURNS JDI has duly filed all tax reports and returns
(including, without limitation, income tax, franchise tax, gross receipts and
sales tax and real personal property tax returns) required to be filed by it and
it has paid all taxes as shown on said returns and all assessments which it has
received to the extent that such have become due or are not being contested in
proceedings with respect thereto. The reserves for taxes reflected in the JDI
Balance Sheet, and carried on JDI's books as of the date hereof, are in the
opinion of JDI adequate, and except as otherwise shown on the JDI Balance Sheet,
there are no pending claims asserted for taxes or assessments against JDI.
4.8 TITLE TO PROPERTIES; ENCUMBRANCES JDI has good and marketable title
to all its material tangible property and assets reflected in the JDI Balance
Sheet (except for properties and assets which since the JDI Balance Sheet Date
have been sold or disposed of in the ordinary course of business), in each case
subject to no mortgage, pledge, lien, conditional sale agreement, option to
purchase, encumbrance or charge of any kind (except liens reflected in the JDI
Balance Sheet or the notes thereto, liens for taxes not yet due, and minor
imperfections of title and encumbrances, if any, which are not substantial in
amount, do not materially detract from the value, or the present or contemplated
use of the property subject thereto, and do not materially impair the operations
of JDI.).
5
4.9 LITIGATION There are no claims, actions, proceedings or
investigations pending, or to the best of JDI's knowledge and belief, threatened
against or affecting JDI which, if adversely determined, would have a material
adverse effect upon the business, properties, operations or prospects, financial
or otherwise of JDI. JDI is not subject to or in default with respect to any
material court or administrative order, writ, injunction, or decree applicable
to it or its business, property or operations.
4.10 CONTRACTS AND OTHER DOCUMENTS JDI is not a party to or bound by
any material written or oral:
a. Employment contract or consulting agreement which is not
terminable (without liability) on thirty (30) days' or less notice
(subject to Indonesian laws and practice on termination of employment);
b. Plan, contract or arrangement for officers or directors, or
for employees generally, with respect to bonuses, incentive
compensation, pensions, deferred compensation or retirement payment, or
any profit sharing, stock option, stock purchase, hospitalization,
insurance or other employee benefit plan otherwise than provided under
standard Indonesian practice;
c. Contract or agreement with any labor or trade union
association;
d. Lease with respect to any property, real, personal or
mixed, whether, as a lessOr or lessee, involving payment of an annual
rental in excess of $10,000 except for lease of JDI office premises in
Wisma Indonesia;
e. Continuing contract or agreement for the future purchase of
any materials, equipment or supplies in excess of normal operating
requirements;
f. Material contract which by its terms requires the consent
of any party thereto to the consummation of the transactions
contemplated hereby;
h. Contract or Commitment for the acquisition or sale of a
material portion of its assets not made in the ordinary course of
business;
i. Contract oR commitment involving payment by JDI of more
than $30,000 in the aggregate following the date hereof or extending
beyond December 31, 2000 and not terminable by JDI prior thereto except
for regular consultants (lawyers, accountants, etc.) fees in the
ordinary course of business or in connection with this transaction;
6
j. Contract or commitment between JDI and any officers,
directors or shareholders of JDI deviating from the ordinary course of
business; or
k. Any other material contract or agreement not of the type
covered by any of the other specific items of this Section 4.10 and not
made in the ordinary course of business.
Seller represents that neither the execution and delivery of this
Agreement nor the consummation of the transactions contemplated hereby will
result in the breach of the terms and conditions of, or constitute a default
under or cause the acceleration of the maturity of, or violate, as the case may
be, any material agreement, lease, mortgage, note, bond, indenture, license or
other document or undertaking, oral or written, to which JDI is a party or by
which it is bound or by which it or any of its properties or assets may be
subject, the breach of, default under, acceleration of or violation of which in
the aggregate would have a material adverse affect upon JDI.
4.11 INSURANCE Seller has delivered to AcuBid and Acquisition Corp. a
schedule which contains a list of all principal policies of fire, life,
liability, ▇▇▇▇▇▇▇'▇ compensation, or other forms of insurance maintained by
JDI.
4.12 EMPLOYEES There are no directors, officers, employees or
consultants of JDI whose current annual compensation is in excess of $50,000.00
(U.S.).
4.13 BANK ACCOUNTS The JDI Schedule sets forth the name of each bank in
which there is an account or safe deposit box of JDI and the names of persons
authorized to draw thereon or to have access thereto.
7
4.14 NO VIOLATION Neither the execution and delivery of this Agreement
nor the consummation of the transactions contemplated hereby will violate or
conflict with (i) the Certificate of Incorporation or By-Laws of JDI or (ii) any
order, writ, injunction or decree of any court, administrative agency or
governmental body to which JDI is a party.
4.15 CORPORATE AUTHORITY The execution and delivery of this Agreement
and the consummation of the transactions contemplated hereby have been duly
authorized by the Board of Commissioners and Shareholders of JDI and no further
corporate authorization on the part of JDI is necessary to consummate the
transactions contemplated herein.
4.16 PENSION TRUST FUNDS JDI has no pension, profit sharing or similar
plan with respect to which any employees of JDI are participants.
4.17 PATENTS AND TRADEMARKS The JDI Schedule is a true and complete
list of all Indonesian trademarks and applications relating thereto owned or
filed or currently in the process of registration by JDI which are of material
importance to the business of JDI as presently conducted. To the best of JDI's
knowledge, JDI has the right and authority to use such patent and trademark
rights in Indonesia in connection with the conduct of its business in the manner
presently conducted and such use does not conflict with, infringe upon, or
violate any patent, trademark or any application relating thereto, of any other
person, firm or corporation.
4.18 DISCLOSURE No representation or warranty of Seller or JDI set
forth in this Agreement contains or will contain any untrue statement of a
material fact or omit to state any material fact necessary to make the
statements herein or therein, in light of the circumstances in which they are
made, not misleading.
4.19 STOCK OWNERSHIP Seller is the record and beneficial owner of no
less than ninety percent (90%) of the issued and outstanding shares of JDI
common stock, and has the full right, power and authority to sell, transfer,
assign and deliver said shares as provided in this Agreement, and, when so sold
to Acquisition Corp. said shares shall be free and clear of any and all liens,
claims, pledges, options, encumbrances and restrictions of whatever nature.
8
4.20 SECURITIES ACT COMPLIANCE
a. Seller represents and warrants that the shares of AcuBid
Common Stock to be acquired by him pursuant to this Agreement will be
acquired for his own account and not with a view to the distribution
thereof within the meaning of the Securities Act of 1933, as amended,
(the "Act") and agrees that any transfer or other disposition of any
shares of AcuBid Common Stock acquired by him hereunder will be made
only pursuant to a registration statement under the Act which has
become effective and is current with respect to the shares of AcuBid
Common Stock being sold, or pursuant to a specific exemption from
registration under the Act but only upon first having obtained the
prior favorable written opinion with respect to such disposition from
AcuBid's counsel at the sole expense of AcuBid.
b. AcuBid may cause to be set forth on the certificates
representing the shares of AcuBid Common Stock issued hereto or on
certificates issued in exchange for all or part of such shares, a
legend to the foregoing effect in form and substance reasonably
satisfactory to AcuBid and AcuBid may issue such "stop transfer"
instructions to its transfer agent in respect of all or any part of
such shares as AcuBid deems reasonably appropriate to prevent
violations of the Act.
c. Seller acknowledges that issuance and sale of the shares of
AcuBid Common Stock to be acquired by him has not been registered under
the Act and that such shares must be held indefinitely unless a
subsequent disposition thereof is registered under the Act or an
exemption from such registration is available. Seller understands that
the exemption from registration afforded by Rule 144 of the General
Rules and Regulations under the Act depends upon the satisfaction of
various conditions and that, if applicable, such rule affords the basis
of sales of shares only in limited amounts and, in the case of
securities to which such rule is not applicable, compliance with
Regulation D or some other exemption of the Act will be required.
9
Seller acknowledges that, except as otherwise provided in this
Agreement, AcuBid has not undertaken to register the shares of AcuBid
Common Stock to be delivered to Seller hereunder and that AcuBid will
have no obligation to effect on behalf of Seller any other exemption
from registration under the Act. AcuBid agrees, however, (i) that it
will not voluntarily withdraw its registration under Section 12 of the
Securities Exchange Act of 1934, as amended, and the rules and
regulations thereunder (the "Exchange Act"), (ii) that it will use its
best efforts to comply timely with the reporting requirements of
Section 13 or 15 (d) of the Exchange Act, and otherwise to keep its
registration under Section 12 of the Exchange Act effective, and (iii)
that it will supply Seller with such information as may be necessary to
enable Seller to make sales of shares of AcuBid Common Stock under Rule
144 or its then equivalent.
ARTICLE V - REPRESENTATIONS AND WARRANTIES OF ACUBID
----------------------------------------------------
AcuBid and Acquisition Corp. hereby, jointly and severally, represent
and warrant to Seller as follows:
5.1 CORPORATE ORGANIZATION; GOOD STANDING AcuBid is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware, and has the corporate power and authority to carry on its own business
as presently conducted. The copies of AcuBid's Certificate of Incorporation and
By-Laws, and all amendments thereto, which have heretofore been delivered to
Seller are complete and correct as of the date hereof. AcuBid is duly qualified
to do business and is in good standing as a foreign corporation in every
10
jurisdiction in which its ownership or leasing of properties requires such
qualification, and, to the extent that the character of the business conducted
by it may require such qualification in any other jurisdiction, the consequences
of the failure so to qualify in the aggregate would not under presently
applicable law have a material adverse affect on its business as now conducted
(financial or otherwise) or the results of its operations.
5.2 CAPITALIZATION As of the date hereof, the authorized capital stock
of AcuBid consists of 50,000,000 shares of common stock, par value $.001 per
share, of which 8,765,408 shares are issued and outstanding, and 10,000,000
shares of Preferred Stock, $.001 par value, none of which is outstanding. There
are no outstanding options, warrants or other rights to subscribe for or
purchase any capital stock of AcuBid or securities convertible into or exchange
for capital stock of AcuBid, except for outstanding options and warrants to
purchase 2,595,000 shares of AcuBid Common Stock. All such issued and
outstanding shares of AcuBid Common Stock are duly authorized, validly issued,
fully paid and non-assessable. Any shares of AcuBid Common Stock which may be
issued upon exercise of AcuBid options or warrants in accordance with the terms
thereof will be duly authorized, validly issued, fully paid and non-assessable.
5.3 SUBSIDIARIES Neither AcuBid nor Acquisition Corp own, directly or
indirectly, any shares of capital stock of any corporation other than
Acquisition Corp., which is a wholly-owned subsidiary of AcuBid. All of the
issued and outstanding stock of Acquisition Corp is owned by AcuBid. The shares
of capital stock of Acquisition Corp stated therein to be owned by AcuBid are so
owned free and clear of all liens, options, charges or encumbrances of any kind,
and are validly issued fully paid and non-assessable, and there are no
outstanding options or agreements of any kind relating to the issuance to any
person of any shares of capital stock or securities convertible into or
exchangeable for capital stock of Acquisition Corp. Acquisition Corp. is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware. As of the date hereof, Acquisition Corp. in not and
has not engaged in any trade or business.
11
5.4 NO VIOLATION Neither the execution and delivery of this Agreement
by AcuBid or Acquisition Corp. nor the consummation of the transactions
contemplated hereby will violate or conflict with (i) the Certificate of
Incorporation or By-Laws of AcuBid or Acquisition Corp., as respectively amended
to date, or (ii) any order, writ, injunction or decree of any court,
administrative agency or governmental body to which AcuBid or Acquisition Corp.
is a party, and will not result in a breach, violation or default or give rise
to an event which, with the giving of notice or after the passage of time, or
both would result in a breach, violation or default of any of the terms or
provisions of any indenture, agreement, judgment, decree or other instrument or
restriction to which AcuBid or Acquisition Corp is a party or by which they may
be bound or affected.
5.5 CORPORATE AUTHORITY The execution and delivery of the Agreement and
the consummation of the transactions contemplated hereby have been duly
authorized by the Board of Directors of AcuBid and Acquisition Corp., and by
AcuBid as sole shareholder of Acquisition Corp. Except for the approval of this
transaction by the shareholders of AcuBid, no further corporate authorization on
the part of AcuBid or Acquisition Corp. is necessary to consummate the
transactions contemplated hereby.
5.6 DISCLOSURE No representation or warranty of AcuBid or Acquisition
Corp. as set forth in the Agreement or the AcuBid Schedule, attached hereto and
made a part hereof, contains or will contain any untrue statement of a material
fact or omit to state any material fact necessary to make the statements herein
or therein, in light of the circumstances in which they are made, not
misleading.
5.7 SEC FILINGS. The AcuBid Common Stock is registered pursuant to
Section 12(g) of the Exchange Act and listed for quotation on the NASDAQ
Over-the-Counter Bulletin Board under the symbol "EBID." AcuBid has filed all
reports, schedules, forms, statements and other documents required to be filed
by it with the Securities and Exchange Commission (the "SEC") pursuant to the
12
reporting requirements of the Exchange Act, including material filed pursuant to
Section 13(a) or 15(d) (all of the foregoing, including filings incorporated by
reference therein, being referred to herein as the "SEC Documents"). AcuBid has
delivered to the Seller true and complete copies of the SEC Documents. As of
their respective dates, the SEC Documents complied, on a timely basis, in all
material respects, with the reporting requirements of the Exchange Act and the
rules and regulations promulgated thereunder, as well as any other federal,
state and local laws, rules and regulations applicable to such SEC Documents,
and none of the SEC Documents contained any untrue statement of a material fact
or omitted to state a material fact required to be stated therein or necessary
in order to make the statements contained therein, in light of the circumstances
in which they are made, not misleading. The financial statements of AcuBid
included in the SEC Documents comply as to form in all material respects with
applicable accounting requirements and the published rules and regulations of
the SEC or other applicable rules and regulations with respect thereto. Such
financial statements have been prepared in accordance with generally accepted
accounting principles applied on a consistent basis during the periods involved
and fairly present in all material respects the financial position of AcuBid as
of the dates thereof and the results of operations and cash flows for the
periods then ended. AcuBid acknowledges that Seller will rely on all of the
aforementioned documents which AcuBid has filed with the SEC.
5.8 NO MATERIAL ADVERSE CHANGE Except as otherwise disclosed in the SEC
Documents, since the date of the most recent balance sheet included in the SEC
Documents, no event has occurred or exists with respect to AcuBid or any of its
subsidiaries which would be likely to have, or has had, a material adverse
effect on AcuBid and its subsidiaries taken as a whole.
5.9 COMPLIANCE WITH LAW Neither AcuBid nor Acquisition Corp. is in
violation of any laws, governmental orders, rules or regulations to which
AcuBid, Acquisition Corp. or any of their respective properties or businesses
are subject, which violation would have a material adverse effect on the
business or operations of any of them.
13
5.10 ISSUANCE OF ACUBID COMMON STOCK The shares of AcuBid Common Stock
to be issued by AcuBid to Seller in exchange for his shares of JDI Stock, and
the Additional Shares to be issued to Zilkha, all as contemplated by this
Agreement, will be duly authorized, validly issued, fully paid and
non-assessable.
ARTICLE VI - COVENANTS
----------------------
Between the date hereof and the Closing Date, AcuBid and Acquisition
Corp. on the one hand, and JDI and Seller on the other hand, respectively,
covenant and agree as follows:
6.1 REGULAR COURSE OF BUSINESS JDI and AcuBid and each of their
respective subsidiaries will carry on their respective business substantially in
the same manner as heretofore. Neither AcuBid nor any of its subsidiaries will
engage in any one or more activities or transactions outside of the ordinary
course of their respective businesses as conducted as of the date hereof which
in the aggregate shall be material to them as a group, and JDI will not engage
in any one or more activities or transactions which shall be outside of the
ordinary course of its business as conducted as of the date hereof which in the
aggregate shall be material to it. Acquisition Corp. will not engage in any
business.
6.2 ADDITIONAL SECURITIES Except as expressly set forth in this
Agreement, neither JDI nor AcuBid or any of its subsidiaries (including
Acquisition Corp.) will issue or sell, or issue options or warrants to purchase,
any capital stock or securities convertible into or rights to subscribe to, or
enter into any agreement or contracts with respect to, any of its capital stock,
or make any other changes in its authorized, issued or outstanding capital
stock, provided that: (i) JDI may issue or sell shares of the JDI Stock upon the
exercise of its options or warrants outstanding as of the date hereof; (ii)
AcuBid may issue or sell shares of its Capital Stock upon the exercise of its
options or warrants outstanding as of the date hereof, all as disclosed in this
Agreement; and (iii) AcuBid shall solicit its shareholders to approve an
amendment to AcuBid's Certificate of Incorporation to increase the authorized
AcuBid Common Stock from 50,000,000 shares to 100,000,000 shares, and AcuBid
shall recommend that its shareholders vote in favor of such amendment.
14
6.3 DIVIDENDS AND DISTRIBUTIONS Neither JDI nor AcuBid shall declare or
pay any dividend on any shares of its capital stock in cash, stock, or property;
make any other distribution with respect to any shares of its capital stock or
directly or indirectly redeem, purchase or otherwise acquire any of its own
capital stock; or make any other distribution of its assets to its shareholders.
6.4 FULL ACCESS JDI and AcuBid and their respective subsidiaries shall
each afford to the officers and authorized representatives of the other full
access to their respective plants, properties, books and records, in order that
each party may have full opportunity to make such investigations as it shall
deem necessary with respect to the affairs of the other; and the officers of
each such party will furnish, and each such party will cause its auditors to
furnish, the other party with such additional financial and operating data and
other information as the other party from time to time reasonably requests. Each
party hereto agrees that it will hold in strict confidence all information
obtained from the other party hereto, that it will not divulge such information
to any other person, firm or corporation or use the same for its own benefit or
for the benefit of any of its subsidiaries or affiliates and that it will return
all such confidential information to the party supplying the same if the sale
herewith is not consummated for any reason. In the event that any investigation
of AcuBid or Seller, as the case may be, results in the discovery of a
misrepresentation or a breach of warranty as to a material matter made by the
other party hereto, then AcuBid or Seller, as the case may be, shall promptly
advise the party that made such misrepresentation or breach of warranty and, if
such misrepresentation or breach can be cured prior to the Closing Date, the
party that made such misrepresentation or breach shall be given an opportunity
to attempt to cure the same. The failure to advise the other party hereto
promptly of the discovery of a misrepresentation or breach of warranty as to a
material matter made by such other party shall not constitute a waiver thereof,
provided such other party shall be given an opportunity to cure the same.
15
6.5 APPROVAL OF SHAREHOLDERS
a. AcuBid will cause a meeting of its shareholders to be duly
called and held as soon as practicable following the date hereof and
will submit and recommend the transactions contemplated by this
Agreement (including, without limitation, increase in the authorized
AcuBid Common Stock from 50,000,000 shares to 100,000,000 shares) to
its shareholders for approval at such meeting, and JDI agrees to use
its best efforts to assist AcuBid in the preparation of any information
required by AcuBid in connection therewith including, without
limitation, a complete description of JDI business and required
financial information.
b. The Seller shall vote all of the JDI Stock owned by Seller
for the approval of this Agreement and the transactions contemplated
hereby prior to the Closing Date.
6.6 SUPPLEMENT TO SCHEDULES AcuBid and Seller each will promptly advise
the other in writing of any matter arising or discovered after the date hereof
which, if existing or known at the date hereof, would have been required to be
set forth or described in any Schedule referred to in this Agreement.
6.7 CONSENTS AcuBid and Seller each agrees to use its best efforts to
obtain any and all third party consents and approvals required by the Agreement
or any Schedule referred to herein for the consummation of the transactions
contemplated hereby.
6.8 FURTHER ASSURANCES Each party hereto agrees to execute and deliver
such instruments and take such other action as the other party may reasonably
require in order to carry out the intent of this Agreement.
16
ARTICLE VII - CONDITIONS PRECEDENT TO SELLER'S OBLIGATIONS
----------------------------------------------------------
Each and every obligation of Seller under this Agreement to be
performed on or before the Closing Date shall be subject to the satisfaction, on
or before the Closing Date, of the following conditions:
7.1 REPRESENTATION AND WARRANTIES TRUE; OBLIGATIONS PERFORMED
a. The representations and warranties made by AcuBid and
Acquisition Corp. in this Agreement shall be true and correct in all
material respects both as of the date of this Agreement and as of the
Closing Date unless otherwise specified herein, and each of AcuBid and
Acquisition Corp shall have delivered to the Seller a certificate
signed by its President and dated the Closing Date to such effect.
b. Each of AcuBid and Acquisition Corp shall have duly and
properly performed, complied with, satisfied and observed its
covenants, agreements, conditions to closing and obligations contained
in this Agreement to be performed, complied with, satisfied and
observed on or before the Closing Date, and each shall have delivered
to the Seller a certificate signed by its President and dated the
Closing date to such effect.
7.2 APPROVAL OF SHAREHOLDERS, ETC. The approval of the shareholders of
AcuBid and Acquisition Corp. referred to in section 6.5 hereof shall have been
obtained in the manner required by applicable law; and all material consents
from third parties required to consummate the transactions contemplated hereby
shall have been obtained. Seller shall have received copies, certified by the
Secretary of AcuBid or Acquisition Corp., as the case may be, of all resolutions
adopted by AcuBid's Board of Directors, by AcuBid as the sole shareholder of
Acquisition Corp. and by Acquisition Corp.'s Board of Directors, with respect to
this Agreement.
7.3 PURCHASE PERMITTED BY APPLICABLE LAWS. The purchase of and payment
for the shares of AcuBid Common Stock to be purchased by Seller hereunder, and
the issuance and sale of such shares to Seller hereunder, shall not be
prohibited by any applicable law or governmental regulation, including, without
limitation, all federal and applicable state securities laws.
17
7.4 NO ADVERSE DECISION. There shall be no action, suit, investigation
or proceeding pending or threatened by or before any court, arbitrator or
administrative or governmental body which seeks to restrain, enjoin, prevent the
consummation of or otherwise affect the transactions contemplated by this
Agreement or questions the validity or legality of any such transactions or
seeks to recover damages or to obtain other relief in connection with any such
transactions.
7.5 DELIVERY OF ACUBID SHARES. AcuBid shall have delivered to Seller
and Zilkha, if applicable, certificates in their respective names for the shares
of AcuBid Common Stock to be acquired by each hereunder.
7.6 APPROVALS AND CONSENTS. AcuBid and Acquisition Corp. each shall
have duly obtained all authorizations, consents, rulings, approvals, licenses,
franchises, permits and certificates, or exemptions therefrom, by or of all
governmental authorities and non-governmental administrative or regulatory
agencies, domestic or foreign, having jurisdiction over them, their respective
assets, this Agreement, the AcuBid Common Stock or the transactions contemplated
hereby, including without limitation, the approval of The NASDAQ
Over-the-Counter Bulletin Board market, if required, and the consents of all
third parties pursuant to existing agreements or instruments by which AcuBid or
Acquisition Corp. is bound, which are required for AcuBid's or Acquisition
Corp.'s execution, delivery and performance of this Agreement and the
consummation of the transactions contemplated hereby, at no cost or other
adverse consequence to Seller, and all thereof shall be in full force and effect
at the time of Closing, and AcuBid and Acquisition Corp. each shall have
delivered to Seller a certificate signed by its President and dated the Closing
Date to such effect (which may be stated to the best knowledge of such
President).
18
7.7 ADVERSE CHANGE. Neither AcuBid nor Acquisition Corp shall have
suffered any material adverse change since the date of this Agreement in its
business, affairs, prospects, financial condition, working capital, assets,
liabilities (absolute, accrued, contingent or otherwise), reserves or
operations, and each shall have delivered to Seller a certificate signed by its
President and dated the Closing Date, to such effect (which may be stated to the
best knowledge of such President).
7.8 OPINIONS OF COUNSEL FOR ACUBID AND ACQUISITION CORP. Seller and
Zilkha, if applicable, shall have received from counsel for AcuBid and
Acquisition Corp. (who may rely in part on opinions of other counsel
satisfactory to Seller's counsel), an opinion dated the Closing Date, in form
and substance reasonably satisfactory to Seller's counsel, to the effect that:
a. AcuBid is a corporation duly organized, validly existing
and in good standing under the laws of its jurisdiction of
incorporation;
b. AcuBid has the corporate power and authority to conduct its
business as now being conducted;
c. The authorized capital stock of AcuBid consists of
100,000,000 shares of Common Stock, par value $.001 per share, and
10,000,000 shares of Preferred Stock, par value $.001 per share, and
the issued and outstanding shares, warrants and options of AcuBid's
capital stock (the number of which shall be stated) have been duly and
validly authorized and issued and are fully paid and non-assessable
with no pre-emptive rights attaching to the ownership thereof.
d. The authorized capital stock of Acquisition Corp. consists
of 1,000 shares of common stock, $.001 par value, of which 100 shares
are issued and outstanding and owned by AcuBid and are fully paid and
non-assessable.
e. The shares of AcuBid Common Stock to be issued to Seller or
Zilkha pursuant to this Agreement are duly authorized and, when issued,
will be validly issued, fully paid and non-assessable;
f. This Agreement has been duly executed and delivered by
AcuBid and Acquisition Corp. and is the valid and binding obligation of
AcuBid and Acquisition Corp., and all corporate action by AcuBid and
Acquisition Corp. required in order to authorize the transactions
contemplated hereby has been duly taken;
19
g. Neither the execution and delivery of this Agreement by
AcuBid or Acquisition Corp., nor the consummation of the transactions
contemplated thereby, will violate the Certificate of Incorporation or
By-Laws of AcuBid or Acquisition Corp., or, to the best of the
knowledge of such counsel, will result in a material violation of any
material contract or agreement to which AcuBid or Acquisition Corp. is
a party or will result in a material default under, or cause any
acceleration in the maturity of, any material obligation to which
AcuBid or Acquisition Corp. is a party (consents having been obtained),
or violate any material order, writ injunction or decree of any court,
administrative agency or governmental body binding upon Acquisition
Corp. or AcuBid.
h. Except as set forth in said opinion, there is no
litigation, proceeding or governmental investigation pending or, to the
best of such counsel's knowledge, threatened against or relating to
AcuBid, its properties or business, officers or directors, or the
transactions contemplated by this Agreement which if adversely
determined could have a material adverse effect on the business,
prospects, properties, assets, results of operations or financial
condition of AcuBid.
In rendering such opinion, counsel may rely on certificates of public
officials and upon certificates of officers of AcuBid and Acquisition Corp. as
to factual matters and on opinions of other counsel of good standing whom they
believe to be reliable as to matters to which the laws of jurisdictions other
than Delaware are applicable.
7.8 No action or proceeding shall have been instituted or threatened
before any court or governmental agency to restrain or prohibit, or to obtain
substantial damages in respect of, this Agreement, or the consummation of the
transactions contemplated herein.
20
7.10 The Bylaws (or any other charter documents specifying the number
of directors) of AcuBid and Acquisition Corp. shall have been amended to provide
for eight (8) directors. All directors of AcuBid and Acquisition Corp. will have
submitted their resignations effective as of the Closing, except for two (2) of
the current directors of each such company, and the Board of each such company
duly shall have appointed six (6) nominees of Seller to fill the vacancies
created by such resignations (or additional unfilled directorships, as the case
may be).
ARTICLE VIII - CONDITIONS PRECEDENT TO THE OBLIGATIONS
------------------------------------------------------
OF ACUBID AND ACQUISITION CORP.
-------------------------------
Each and every obligation of AcuBid and Acquisition Corp. under this
Agreement to be performed on or before the Closing Date shall be subject to the
satisfaction, on or before the Closing Date, of the following conditions:
8.1 REPRESENTATIONS AND WARRANTIES TRUE; OBLIGATIONS PERFORMED
a. The representations and warranties made by JDI and Seller
in this Agreement shall be true and correct in all material respects at
and as of the Closing Date as though such representations and
warranties were made at and as of such time, except for any changes
permitted by the terms hereof or consented to by AcuBid and except for
any matters the aggregate cumulative effect of which on the financial
condition, results of operations, prospects or assets of JDI and its
subsidiaries taken as a whole, is not materially adverse.
b. JDI and Seller shall have performed and complied in all
material respects with all obligations and agreements required by this
Agreement to be performed and complied with by JDI and Seller prior to
the Closing Date.
c. JDI shall have delivered to AcuBid and Acquisition Corp. a
certificate of its President Director, dated the Closing Date,
certifying to the fulfillment of both of the forgoing conditions.
21
8.2 APPROVAL OF SHAREHOLDERS, ETC. The approval of the shareholders of
AcuBid and Acquisition Corp. referred to in Section 6.5 hereof shall have been
obtained in the manner required by applicable law; and all material consents
from third parties required to consummate the transactions contemplated hereby
shall have been obtained. AcuBid and Acquisition Corp. shall have received
copies, certified by the President Director of JDI of all resolutions adopted by
JDI's Board of Directors and Board of Commissioners and shareholders with
respect to the approval of this Agreement and the transactions contemplated
thereby.
8.3 OPINION OF COUNSEL FOR JDI AcuBid and Acquisition Corp. shall have
received from counsel for JDI and Seller (who may rely in part on opinions of
other counsel satisfactory to AcuBid's counsel), an opinion dated the Closing
Date, in form and substance reasonably satisfactory to AcuBid's counsel, to the
effect that:
a. JDI is a corporation duly organized, validly existing and
in good standing under the laws of its jurisdiction of incorporation;
b. JDI has the corporate power and authority to conduct its
business as now being conducted;
c. The authorized capital stock of JDI consists of
20,000,000,000 shares of Common Stock, par value 25 Indonesian Rupiahs
per share, and the issued and outstanding shares of JDI's capital stock
(the number of which shall be stated) have been fully and validly
authorized and issued and are fully paid and non-assessable;
d. This Agreement has been duly executed and delivered by JDI
and is a valid and binding obligation of JDI; and all corporate action
by JDI required in order to authorize the transactions contemplated
hereby has been duly taken;
e. Subject to Sections 12.11 and 12.17 herein, neither the
execution and delivery of this Agreement by JDI, nor the consummation
of the transactions contemplated thereby, will violate the Certificate
of Incorporation or By-Laws of JDI, or, to the best of the knowledge of
such counsel, will result in a material violation of any material
contract or agreement to which JDI is a party or will result in a
material default under, or cause any acceleration in the maturity of,
any material obligation to which JDI is a party (consents having been
obtained), or violate any material order, writ injunction or decree of
any court, administrative agency or governmental body binding upon JDI.
22
f. This Agreement and all other agreements and instruments to
be executed in connection herewith by Seller have been fully executed
and delivered by Seller and constitute the legal, valid and binding
obligation of Seller, except as limited by bankruptcy, insolvency or
other laws affecting generally the enforcement of creditors' rights;
g. Seller has full right, power, legal capacity and authority
to enter into this Agreement and to sell, transfer and deliver to
Acquisition Corp. the shares of JDI Stock as provided in this
Agreement; and that upon delivery of certificates representing said
shares in accordance with the terms of this Agreement, good and
marketable title thereto, free and clear of any and all claims, liens,
charges, restrictions, encumbrances and equities, will pass to
Acquisition Corp. and
h. Except as set forth in said opinion, there is no
litigation, proceeding or governmental investigation pending or, to the
best of such counsel's knowledge, threatened against or relating to
JDI, its properties or business, officers or directors, or the
transactions contemplated by this Agreement which if adversely
determined could have a material adverse effect on the business,
prospects, properties, assets, results of operations or financial
condition of JDI.
In rendering such opinion, counsel may rely on certificates of public
officials and upon certificates of Seller and officers of JDI as to factual
matters and on opinions of other counsel of good standing whom they believe to
be reliable as to matters to which the laws of jurisdictions other than
Indonesia are applicable.
8.4 No action or proceeding shall have been instituted or threatened
before any court or governmental agency to restrain or prohibit, or to obtain
substantial damages in respect of, this Agreement, or the consummation of the
transactions contemplated herein.
8.5 PURCHASE PERMITTED BY APPLICABLE LAWS. The purchase of and payment
for the shares of AcuBid Common Stock to be purchased by Seller hereunder, and
the issuance and sale of such shares to Seller hereunder, shall not be
prohibited by any applicable law or governmental regulation, including, without
limitation, all federal and applicable state securities laws.
23
8.6 NO ADVERSE DECISION. There shall be no action, suit, investigation
or proceeding pending or threatened by or before any court, arbitrator or
administrative or governmental body which seeks to restrain, enjoin, prevent the
consummation of or otherwise affect the transactions contemplated by this
Agreement or questions the validity or legality of any such transactions or
seeks to recover damages or to obtain other relief in connection with any such
transactions.
8.7 DELIVERY OF JDI SHARES. Seller shall have delivered to Acquisition
Corp. certificates evidencing the JDI Stock to be transferred hereunder,
registered in the name of Acquisition Corp.
8.8 APPROVALS AND CONSENTS. Seller and JDI each shall have duly
obtained all authorizations, consents, rulings, approvals, licenses, franchises,
permits and certificates, or exemptions therefrom, by or of all governmental
authorities and non-governmental administrative or regulatory agencies, domestic
or foreign, having jurisdiction over them, their respective assets, this
Agreement, the JDI Stock or the transactions contemplated hereby, and the
consents of all third parties pursuant to existing agreements or instruments by
which Seller or JDI is bound, which are required for Seller's or JDI's
execution, delivery and performance of this Agreement and the consummation of
the transactions contemplated hereby, at no cost or other adverse consequence to
AcuBid or Acquisition Corp., and all thereof shall be in full force and effect
at the time of Closing, and Seller and JDI each shall have delivered to AcuBid
and Acquisition Corp. a certificate signed by Seller or JDI's President, as the
case may be, and dated the Closing Date to such effect (which may be stated to
the best knowledge of such person).
24
8.9 ADVERSE CHANGE. JDI shall not have suffered any material adverse
change since the date of this Agreement in its business, affairs, prospects,
financial condition, working capital, assets, liabilities (absolute, accrued,
contingent or otherwise), reserves or operations, and JDI shall have delivered
to AcuBid and Acquisition Corp. a certificate signed by its President and dated
the Closing Date, to such effect (which may be stated to the best knowledge of
such President).
8.10 EMPLOYMENT AGREEMENT. AcuBid shall have entered into an employment
agreement with ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ on the following principal terms: ▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇ shall agree to serve as Chief Executive Officer for a period of five
(5) years. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ shall receive $150,000 in annual compensation along
with an agreed upon qualified option package. The Board of Directors of AcuBid
may at any time terminate ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ by providing him with a severance of
1-1/2 years of compensation at any time during the first year; 1 year of
compensation during the next 3 years, and 1/2 year of compensation for the last
year. Similar packages shall be provided to ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ and ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
at their present salary levels at AcuBid. Notwithstanding anything to the
contrary in this Agreement, such employment agreements (including, without
limitation, the agreed upon qualified option packages) shall be subject to
Seller's reasonable approval, provided, however, that the foregoing term "agreed
upon qualified option package" shall mean as agreed to by Seller and such
employees.
ARTICLE IX -- CLOSING.
----------------------
9.1 The Closing under this Agreement shall take place at a mutually
agreed upon location upon five (5) days prior written notice from AcuBid to
Seller or at such other time and place as mutually may be agreed upon by the
parties hereto; provided, however, that the Closing shall take place no later
than August 31, 2000. The time and date of the Closing is referred to in this
Agreement as the "Closing Date".
a. On the Closing Date, Seller and JDI shall deliver or cause
to be delivered to AcuBid and Acquisition Corp. the following:
i. Certificates representing all of the shares of JDI
Stock to be acquired by Acquisition Corp. hereunder,
registered in the name of Acquisition Corp;
25
ii. The certificates, executed by JDI, referred to in
paragraphs 8.1 (c) and 8.2;
iii. The opinion of counsel for Seller referred to in
paragraph 8.3;
iv. Such other documents and instruments as
reasonably may be requested by, and in form and substance
satisfactory to, counsel for AcuBid and Acquisition Corp.;
b. On the Closing Date, AcuBid and/or Acquisition Corp. shall
deliver to Seller the following:
i. Stock certificates registered in the name of
Seller and Zilkha, if applicable, representing the number of
shares of AcuBid Common Stock to be received by each
hereunder:
ii. The certificates of the respective Presidents of
AcuBid and Acquisition Corp. referred to in Article VII;
iii. An opinion of counsel for AcuBid and Acquisition
Corp. referred to in paragraph 7.8;
iv. Certified copies of resolutions referred to in
paragraph 7.2;
v. Corporate and tax good standing certificates of
AcuBid and Acquisition Corp from the respective jurisdiction
in which they are incorporated or transact business;
vi. Certified copies of the Articles of Incorporation
and Bylaws of AcuBid and Acquisition Corp;
vii. The written resignation of the directors of
AcuBid and Acquisition Corp and all documents necessary to
elect or appoint the appropriate individuals to such positions
in accordance with this Agreement, all as provided in Section
7.10;
viii. All documents necessary or appropriate to
change the authorized signatories of AcuBid's and Acquisition
Corp's bank accounts and to otherwise take possession and full
operational control of AcuBid and Acquisition Corp and their
respective assets; and
26
ix. Such other documents and instruments as
reasonably may be requested by, and in form and substance
satisfactory to, counsel for the Seller.
ARTICLE X - TERMINATION OF REPRESENTATIVE
-----------------------------------------
AND WARRANTIES; SURVIVAL OF COVENANTS
-------------------------------------
The respective representations and warranties of Acubid, Acquisition
Corp., JDI, and Seller contained in this Agreement shall expire and terminate on
the Closing Date. The obligations under all covenants and agreements which are
to be performed after the Closing Date shall survive the Closing Date. All other
covenants, agreements, and certificates shall expire and terminate on the
Closing Date.
ARTICLE XI - REGISTRATION RIGHTS
--------------------------------
11.1 DEFINED TERMS. As used in this Article XI, the following terms
shall have the following respective meanings:
a. "Eligible Shareholders" shall mean Seller, Zilkha and any
Transferee holding Restricted Stock.
b. "Maximum Includable Underwritten Shares" shall mean the
maximum number of shares of Acubid Common Stock and other classes of
stock of Acubid that a managing or principal underwriter, in its good
faith judgment, deems it practicable to offer and sell at that time in
a firm commitment underwritten offering at a reasonable price.
c. "Prospectus" shall mean any Preliminary Prospectus and
final Prospectus (as such may be amended or supplemented) which
constitutes Part I of a Registration Statement filed with the SEC.
d. "Registration Expenses" shall mean all expenses arising out
of or related to the preparation, filing, amendment and supplementing
of a Registration Statement, including, without limitation, all legal
and accounting fees, transfer agents' and registrars' fees, SEC filing
fees, NASD filing fees, printing costs, registration or qualification
fees and expenses to comply with "blue sky" or other state securities
laws, the fees of other experts, and any expenses or other compensation
paid to the underwriters; provided however, that Registration Expenses
shall not include underwriting commissions and discounts and transfer
taxes, if any, payable in connection with the sale of shares of Acubid
Common Stock, and any legal fees for counsel to a Holder.
28
e. "Restricted Stock" shall mean the shares of Acubid Common
Stock received by Seller or Zilkha pursuant to this Agreement
(restricted only in terms of the Act), whether held by such persons or
by any Transferee; provided, however, that shares of Acubid Common
Stock transferred by an Eligible Shareholder pursuant to an effective
Registration Statement or amendment thereto, or in a transaction
permitted by Rule 144 under the Act, or any successor rule or
regulation, or shares of Acubid Common Stock no longer subject to any
restriction against transferability under the Act, shall not thereafter
be considered Restricted Stock.
f. "Holder" shall mean each holder of Restricted Stock for
whom shares are included or proposed to be included in a Registration
Statement filed or to be filed by Acubid.
g. "Transfer" shall include any sale, pledge, assignment,
encumbrance or other disposition of any shares of Restricted Stock or
of any part thereof or interest therein.
h. "Transferee" shall mean any person to which Seller or
Zilkha shall have Transferred Restricted Stock in compliance with an
available exemption from registration under the Act, to the extent that
any of such persons shares remain Restricted Stock after such Transfer.
i. "Market Value" shall mean the mean between the bid and
asked quotations in the over the counter market as determined by the
NASDAQ system for the 10 trading days immediately prior to the date of
the includable shares notice.
11.2 INCIDENTAL REGISTRATIONS.
29
a. If at any time Acubid proposes to file on its behalf and/or
on behalf of any of its security holders a Registration Statement under
the Act on form S-1, or on any other form for the general registration
of securities to be sold for cash with respect to any class of equity
security (as defined in Section 3(a)(11) under the Exchange Act),
Acubid shall be required to give written notice to each Eligible
Shareholder at least thirty (30) days before the filing with the
Commission of such Registration Statement. The notice shall offer to
include in such filing on the same terms and conditions as the
securities proposed to be included in such Registration Statement of
Acubid and/or any of its security holders such number of shares of
Restricted Stock as the Eligible Shareholders may request, subject to
the limitations hereinafter set forth. Those Eligible Shareholders
desiring to have Restricted Stock registered under this section 11.2
shall be required (i) to so advise Acubid in writing within twenty (20)
days after the date of receipt of such offer from Acubid, setting for
the number of shares of Restricted Stock for which registration is
requested, and (ii) to deliver to Acubid a letter from counsel (who
shall be reasonably satisfactory to Acubid) for those Eligible
Shareholders requesting registration to the effect that registration
under the Act of the proposed sale of such Restricted Stock is required
under the Act in order to Transfer such Restricted Stock in the manner
contemplated. Acubid shall thereupon include in such filing subject to
the limitations hereinafter set forth, the Restricted Stock proposed to
be offered for sale by the Eligible Shareholders making such request,
on the same terms and conditions as the securities proposed to be
included in such filing on behalf of Acubid and/or any of its security
holders, and shall use its best efforts to effect registration under
the Act of the sale of such shares.
b. The right of the Eligible Shareholders to have Restricted
Stock included in any Registration Statement filed by Acubid in
accordance with the provisions of this Section 11.2 shall be subject to
the following limitations and conditions:
i. Acubid shall, in its sole discretion, select the
underwriter or underwriters, if any, who are to undertake the
sale and distribution of the Restricted Stock to be included
in a Registration Statement filed under the provisions of this
Section 11.2;
30
ii. In the event the Registration Statement proposed
to be filed by Acubid pursuant to this Section 11.2 shall be,
in whole or in part, for a firm commitment underwritten
primary public offering of securities of Acubid, Acubid shall,
as soon as practicable after the expiration of the twenty (20)
day period provided for in Section 11.2(a) furnish each Holder
with a written statement of the managing or principal
underwriter as to the Maximum Includable Underwritten Shares
(the "Includable Shares Notice"). If the total number of
shares of Acubid Common Stock and other classes of stock of
Acubid proposed to be included in such underwritten public
offering is in excess of the Maximum Includable Underwritten
Shares, the number of shares of Restricted Stock to be
included within the coverage of such Registration Statement
and which are to be underwritten shall be reduced to the
Maximum Includable Underwritten Shares as follows: (A) First,
AcuBid shall be entitled to include all securities it proposes
to sell; (B) Second, the Holders (on a pro rata basis or as
they otherwise may agree) shall be entitled to include the
shares of Restricted Stock as to which they have requested
registration to the extent that such shares, together with the
shares to be included under clause (A), do not exceed the
Maximum Includable Underwritten Shares; and (C) any other
security holders with registration rights shall be entitled to
include their securities to the extent that such securities,
together with the shares to be included under clauses (A) and
(B), do not exceed the Maximum Includable Underwritten Shares.
c. No reduction shall be made in the number or amount or
securities to be registered for the account of Acubid;
d. The right to required incidental registration of shares of
Restricted Stock under this Section 11.2 shall terminate upon the
expiration of five (5) years following the Closing Date.
e. Anything contained in this Section 11.2 to the contrary
notwithstanding, the right to require incidental registration of shares
of Restricted Stock hereunder shall not apply to a Registration
Statement relating to an offering solely for the account of security
holders of a single corporation with respect to securities issued or to
be issued by Acubid in connection with the acquisition of the stock or
assets, or the merger or consolidation, of such corporation by or with
Acubid, which Registration Statement is filed by Acubid within ninety
(90) days following the closing of such acquisition.
f. Acubid agrees to furnish each Holder with such number of
copies of the Prospectus as such Holder may reasonably request in order
to facilitate the sale and distribution of his Restricted Stock.
31
11.3 REQUESTED REGISTRATIONS.
a. If any Eligible Shareholder proposes, on or after the later
of July 31, 2000 or thirty (30) days after the Closing Date to offer
for sale, sell or transfer any Restricted Stock pursuant to Section 5
of the Act, then they will give Acubid written notice to that effect
specifying the number of shares proposed to be sold, the identity of
the proposed underwriter and the plan for distribution of such shares.
Such notice shall be delivered to Acubid, together with a letter from
counsel (who shall be reasonably satisfactory to Acubid) for such
Eligible Shareholder to the effect that registration under the Act of
the proposed sale of such Restricted Stock is required under the Act in
order to Transfer such Restricted Stock in the manner contemplated.
b. If and when Acubid shall be required by the provisions of
this Section 11.3 to effect the registration of any Restricted Stock
under the Act, Acubid will, as expeditiously as possible:
i. Give written notice to all Eligible Shareholders,
who were not a party to the aforementioned notice to Acubid
requesting registration of shares, advising them of its
intention to effect a proposed registration and to include in
such proposed registration the shares of Restricted Stock
which any such Eligible Shareholder requests Acubid to
register, provided such request is furnished to Acubid in
writing within twenty (20) days after the date of receipt of
the aforesaid notice from Acubid.
ii. Prepare and file a Registration Statement on Form
S-1, or other form for the general registration of securities
as may be appropriate (giving effect to the plan or
distribution of the Restricted Stock proposed to be
transferred), and use its best efforts to cause such
Registration Statement to become effective in order that the
Holders may sell their Restricted Stock in accordance with
their proposed plan of distribution.
iii. Prepare and file with the SEC such amendments
and supplements to such Registration Statement and the
prospectus used in connection therewith as may be necessary to
keep such Registration Statement effective and to comply with
the provisions of the Act with respect to the offer of the
Restricted Stock covered by such Registration Statement during
the period required by the Holders for distribution of the
Restricted Stock; and
32
iv. Furnish to each Holder such number of copies of
the Prospectus as such Holder may reasonably request in order
to facilitate the transfer of the Restricted Stock.
c. The right of the Eligible Shareholders to have Restricted
Stock registered under the Act pursuant to the provisions of this
section 11.3 shall be subject to the following limitations and
conditions:
i. If a request for registration is made within
thirty (30) days prior to or following the conclusion of
Acubid's then current fiscal year, Acubid shall have the right
to delay the filing of a Registration Statement for a period
of ninety (90) days, or for such a period in time until Acubid
receives its audited financial statements for such fiscal
year, whichever first occurs;
ii. In the event that the Holders request to sell
Restricted Stock in an underwritten offering and fifty (50%)
percent or more of the Market Value (as determined in
accordance with Section 11.2(b)) of the Acubid securities
proposed to be included in any such Registration Statement
shall be for the account of Acubid and any Shareholders of
Acubid other than Eligible Shareholders, then Acubid shall
have the right to select the underwriter or underwriters to
undertake the sale of the stock included in the Registration
Statement. If more than fifty (50%) percent of the Market
Value of the Acubid securities proposed to be included in any
such Registration Statement shall be for the account of
Eligible Shareholders, then the Holders shall have the right
to select the underwriter or underwriters who are to undertake
the sale and distribution of Restricted Stock to be included
in a Registration Statement filed under the provisions of this
Section 11.3, subject to the prior approval thereof by Acubid,
which approval will not be unreasonably withheld or delayed;
33
iii. The Eligible Shareholders shall not be entitled
to request more than one (1) Registration Statement under the
provisions of this Section 11.3; provided, however, if more
than fifty (50%) percent of the Market Value (as determined
pursuant to Section 11.2(b)) of the Acubid securities included
in any such Registration Statement shall be for the account of
Acubid and any shareholders of Acubid other than Eligible
Shareholders, then such Registration Statement shall not
constitute a Registration Statement requested by Eligible
Shareholders for the purpose of this Section 11.3 but shall be
deemed an incidental registration under Section 11.2;
iv. Any request for a Registration Statement required
to be filed by Acubid pursuant to this Section 11.3 shall be
made by Eligible Shareholders owning beneficially a minimum of
5,000,000 shares of Restricted Stock who propose to register
up to 17,500,000 shares of Restricted Stock in such
Registration Statement;
v. The shares of Restricted Stock referred to in this
Section 11.3 shall be adjusted to reflect any changes in the
capitalization of Acubid through reorganization,
re-capitalization, stock split, stock dividend, combination of
shares, merger, consolidation or otherwise;
vi. Acubid shall have the right to include any Acubid
securities in any Registration Statement filed by Acubid
pursuant to this Section 11.3; provided, however, if the
managing underwriter determines that the total number of
Acubid securities proposed to be included in any such
Registration Statement exceeds the Maximum Includable
Underwritten Shares, then all of the Acubid securities
proposed to be included in such Registration Statement by
Acubid and by any other shareholders of Acubid, shall be
excluded from such Registration Statement before any shares to
be offered by the Holders shall be excluded; provided,
further, if the managing underwriter determines that the
number of Acubid securities proposed to be included in such
Registration Statement should be further reduced, then such
reduction shall be pro rata based upon the number of shares of
Acubid Common Stock which each Holder requested to have
registered (unless the Holders have agreed to a different
allocation);
vii. Acubid shall not be required to file a
Registration Statement on behalf of any Eligible Shareholder
pursuant to the provisions of this Section 11.3 within a
period of six (6) months after the effective date of any
Registration Statement filed by Acubid with respect to which
Acubid complied with the incidental registration provisions of
34
Section 11.2; provided, however, that Acubid shall have
registered all of the shares of Restricted Stock with respect
to which registration was requested by such Eligible
Shareholder and such registration shall have remained
effective for a period of not less than thirty (30)
consecutive days (unless all such shares of Restricted Stock
were previously sold pursuant to such registration); and
viii. The right to require registration of Restricted
Stock under this Section 11.3 shall terminate upon the
expiration of five (5) years following the Closing Date.
11.4 GENERAL
a. Acubid shall have sole control in connection with
preparing, filing, withdrawing, amending or supplementing any
Registration Statement under the Act to be filed on behalf of the
Holders.
b. Acubid shall use its best efforts to register or qualify
the Restricted Stock covered by any Registration Statement under the
Act filed on behalf of any Holder under such securities or Blue Sky
laws in such jurisdictions as the Holders may reasonably request;
provided, however, that Acubid reserves the right, in its sole
discretion, not to register or qualify shares of Restricted Stock in
any jurisdiction where such shares do not meet the requirements of such
jurisdiction, or where registration or qualification would be contrary
to Acubid's best interests.
c. In the event any Eligible Shareholder proposed to include
his or its Restricted Stock in any Registration Statement filed
pursuant to Section 11.2 and said Restricted Stock is proposed to be
sold in an underwritten offering, such Eligible Shareholder agrees to
enter into an underwriting agreement containing customary terms and
conditions.
11.5 INDEMNIFICATION In the event of the registration of any Restricted
Stock under the Act pursuant to the provisions of this Agreement, AcuBid agrees
to indemnify and hold harmless the Holder of such Restricted Stock, each
underwriter, if any, of such Restricted Stock, and each person who controls such
Holder or any such underwriter within the meaning of Section 15 of the Act, from
35
and against any and all losses, claims, damages or liabilities, joint or
several, to which such Holder, underwriter or controlling person may become
subject under the Act or at common law or otherwise, insofar as such losses,
claims, damages or liabilities (or actions in respect thereof) arise out of or
are based upon any untrue statement or alleged untrue statement of any material
fact contained, on the effective date thereof, in any Registration Statement
under which such Restricted Stock was registered under the Act, and Prospectus
contained therein, or any amendment or supplement thereto or arise out of or are
based upon the omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not
misleading, or (in the case of a Prospectus) necessary to make the statements
therein, in light of the circumstances under which they were made, not
misleading; and will reimburse such Holder, each such underwriter, and each such
controlling person for any legal or any other expenses reasonably incurred by
such Holder, underwriter or controlling person in connection with investigating
or defending any such losses, claim, damages, liability or action; provided,
however, that AcuBid will not be liable in any such case to the extent that any
such loss, claim, damage or liability arises out of or is based upon an untrue
statement or alleged untrue statement or omission or alleged omission made in
such Registration Statement, such Prospectus or such amendment or supplement in
reliance upon and in conformity with written information furnished to AcuBid by
such Holder, underwriter or controlling person specifically for use in
preparation thereof.
In the event of the registration of any Restricted Stock under the Act
pursuant to the provisions hereof, each Holder of Restricted Stock, each
underwriter, if any, of such Restricted Stock, and each person who controls such
Holder or any such underwriter within the meaning of Section 15 of the Act,
severally and not jointly agrees to indemnify and hold harmless AcuBid, each
person who controls AcuBid within the meaning of Section 15 of the Act, each of
its officers who signs the Registration statement and each director of AcuBid,
from and against any losses, claims, damages or liabilities, joint or several,
to which AcuBid, such controlling person or any such officer or director may
36
become subject under the Act or at common law or otherwise, insofar as such
losses, claims, damages or liabilities (or actions in respect thereof) arise out
of or are based upon any untrue statement or alleged untrue statement of any
material fact contained, on the effective date thereof, in any Registration
Statement under which such Restricted Stock was registered under the Act, any
Prospectus contained therein, or amendment or supplement thereto, or arise out
of or are based upon the omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements
therein not misleading, or (in the case of a Prospectus) necessary to make the
statements therein, in light of the circumstances under which they were made,
not misleading, which untrue statement or omission or alleged omission was made
therein in reliance upon and in conformity with, written information furnished
to AcuBid by such Holder, controlling person or underwriter, specifically for
use in connection with the preparation thereof; and will reimburse AcuBid, such
controlling person or each such officer or director for any legal or any other
expenses reasonably incurred by them in connection with investigating or
defending any such loss, claim, damage, liability or action.
Promptly after receipt by an indemnified party of notice of the
commencement of any action, such indemnified party will, if a claim in respect
thereof is to be made against any indemnifying party, give written notice to
such indemnifying party of the commencement thereof, but the omission so to
notify the indemnifying party will not relieve it from any liability to which it
may have to any indemnified party otherwise than pursuant to the provisions of
this Section 11.5. In case any such action is brought against any indemnified
party, and it notifies any indemnifying party of the commencement thereof, the
indemnifying party will be entitled to participate in, and to the extent that it
may wish, jointly with any other indemnifying party similarly notified, to
assume the defense thereof, with counsel satisfactory to such indemnified party,
and after notice from the indemnifying party to such indemnified party of its
election so to assume the defense thereof, the indemnifying party will not be
liable to such indemnified party for any legal or other expenses subsequently
incurred by such indemnified party in connection with the defense thereof, other
than the reasonable cost of investigation.
37
11.6 EXPENSES.
a. In connection with any incidental registration on behalf of
the Eligible Shareholders of any Restricted Stock under the Act
pursuant to the provisions of Section 11.2 of this Agreement, AcuBid
shall pay all Registration Expenses.
b. In connection with the requested registration on behalf of
the Eligible Shareholders of any Restricted Stock under the Act
pursuant to the provisions of Section 11.3 of this Agreement, AcuBid
shall pay all Registration Expenses, except that the Holders shall pay
SEC, NASD and Blue Sky registration and filing fees attributable solely
to inclusion of the Holders' shares of Restricted Stock in such
Registration Statement and the related filings under Blue Sky laws.
11.7 TRANSFEREES In the event that any shares of the Restricted stock
shall at any time be transferred of record by any Eligible Shareholder other
than pursuant to an effective Registration Statement or pursuant to Rule 144 of
the Act, the rights herein conferred upon such Eligible Shareholder shall extend
to the transferee of such shares, subject in any event to the limitations and
conditions set forth herein.
11.8 EXISTING REGISTRATION RIGHTS. AcuBid represents and warrants that
the only outstanding registration rights held by other security holders of
AcuBid are incidental or "piggyback" registration rights for "to include . . .
shares in up to two (2) registration statements filed by [AcuBid] to the extent
[AcuBid], any underwriter and any other party to the registration statement deem
it feasible to include such shares."
ARTICLE XII - MISCELLANEOUS PROVISIONS
--------------------------------------
12.1 GOVERNING LAW This Agreement and the legal relations between the
parties shall be governed by and construed in accordance with the laws of the
State of Delaware, except insofar as the internal law of any other political
entity or jurisdiction shall specifically and mandatorily apply to any of the
transactions contemplated hereby.
38
12.2 AMENDMENT AND MODIFICATION Subject to applicable law, this
Agreement may be amended, modified and supplemented by mutual written agreement
of the respective parties hereto, at any time prior to the Closing Date with
respect to any of the terms contained herein, whether before or after the
approval of this Agreement by the shareholders of AcuBid: provided, however,
that no such amendment, modification or supplement may be executed which would
materially and adversely affect the rights of AcuBid shareholders after approval
by AcuBid shareholders.
12.3 ASSIGNMENT This Agreement and all of the provisions hereof shall
be binding upon and inure to the benefit of the parties hereto and their
respective successors and permitted assigns, but, except as otherwise provided
herein, neither this Agreement nor any of the rights, interests or obligations
hereunder shall be assigned by any of the parties hereto without the prior
written consent of each of the other parties.
12.4 NOTICES All notices, requests, demands, and other communications
hereunder shall be deemed to have been duly given if delivered by hand or
mailed, certified or registered mail, with postage prepaid:
a. if to AcuBid or Acquisition Corp.
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
with a copy to:
▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
b. If to JDI or Seller
Wisma Indovision
Mezzanine Floor
JI. Raya Panjang
Z/lll Green Garden
Jakarta 11520, Indonesia
Attn: Dewi A.L. Gontha
with a copy to:
▇▇▇▇ ▇▇▇▇▇▇▇▇
Minang ▇▇▇▇▇▇ ▇▇▇▇▇▇ & Associates
▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇
▇▇. Jend. ▇▇▇▇▇▇▇▇
▇▇▇. ▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇
39
or to such other person or address as may be designated in writing in accordance
with this Section 12.4
12.5 BROKERS AcuBid and Acquisition Corp., on the one hand, and JDI and
Seller, on the other hand represent, warrant and agree with the other, that no
brokers, agents or finders are entitled to any brokerage fee, finder's fee,
commission or other compensation on account of this Agreement or any matter
contemplated hereby. Each party hereto agrees to indemnify and hold the other
parties harmless form and against any and all claims and liabilities for
brokerage commissions or finders' fees brought by any person incurred as a
result of any action taken by such indemnifying party.
12.6 COUNTERPARTS This Agreement may be executed simultaneously in two
or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument.
12.7 HEADINGS The headings of the Articles and Sections of this
Agreement are inserted for convenience only and shall not constitute a part
hereof.
12.8 ENTIRE AGREEMENT This Agreement, including other documents
referred to herein which form a part hereof, contains the entire understanding
of the parties hereto in respect of the subject matter contained herein. There
are no restrictions, promises, warranties, covenants, or undertakings, other
than those expressly set forth herein. This Agreement supersedes all prior
agreements and understandings between the parties with respect to such subject
matter.
40
12.9 EXPENSES Each of the parties hereto will pay its own fees and
expenses, including its own counsel fees and accountants' fees, incurred in
connection with this Agreement or any transaction contemplated by this
Agreement.
12.10 WAIVER Any condition to a party's obligation hereunder may be
waived in writing by such party.
12.11 FOREIGN INVESTMENT APPROVAL The sale and transfer by the Seller
of his shares in JDI as contemplated herein is subject to the approval of the
Indonesian capital investment authority (the Badan Penanaman Modal, BPM) and
that of the Ministry of Law and Legislation (MOLAL) to the amended Articles of
Association of JDI. The Seller warrants to arrange for and file the BPM
application as soon as practicable upon the execution of this Agreement.
12.12 TRANSFER OF JDI SHARES It is acknowledged and agreed that it is
the intention of the Seller to transfer the JDI Stock to an offshore entity (the
"Third Party") subsequent to execution hereof and prior to the Closing Date.
AcuBid and Acquisition Corp. hereby agree to such transfer by the Seller
(subject only to notice of such transfer to be made to them in writing). The
parties herein acknowledge that subsequent to such transfer, the Third Party
shall be deemed to be substituted in this Agreement in place of the Seller and
all the Seller's rights and obligations in this Agreement shall transfer to the
Third Party as if this Agreement had been executed by the Third Party, and
Seller shall be released from his obligations under this Agreement.
41
12.13 ANNOUNCEMENTS/CONFIDENTIALITY
(a) None of the parties shall, without prior written consent
of the others make or authorize any announcement concerning the subject
matter of this Agreement or any matter ancillary thereto otherwise than
as may be required by law or applicable regulatory requirements. In the
event that this Agreement lapses for any reason whatsoever, the parties
agree to keep all information related to hereto confidential. This
provision shall survive termination of this Agreement.
(b) The parties hereto agree that the information exchanged
between them prior to and after Closing Date is and shall remain the
property of the party disclosing it (the "Discloser"). No written
information disclosed by a party to the other party shall be copied
and/or reproduced without the express written permission of the
Discloser. The parties herein specifically agree that they shall not,
and they shall ensure that the present Directors, officers and
employees of JDI, AcuBid and Acquisition Corp. (the "Companies") shall
not, disclose any information pertaining to the Companies to any third
party, without the express permission in writing of the other parties
herein.
12.14 ARBITRATION
(a) Any and all disputes, controversies, and conflicts between
the parties herein in connection with this Agreement shall, so far as
possible, be settled amicably.
(b) Failing such amicable settlement, any and all disputes,
controversies and conflicts arising out of or in connection with this
Agreement or its performance (including the validity or this Agreement)
shall be settled by arbitration by a one (1) member arbitration board
which will hold its sessions in the United States in English under the
ICC (International Chamber Commerce) Rules. The tribunal of one (1)
arbitrator shall be appointed by the Chairman of the ICC.
42
(c) The one (1) member of the board of arbitration shall be
appointed in accordance with the ICC Rules regarding the appointment of
arbitrators.
(d) The arbitral proceeding shall accord to each of the
parties the right of cross-examination of witnesses, the right to
provide witnesses including expert witnesses, and the right to make
both written and oral submissions.
(e) The arbitral award made and granted by the arbitrators
shall be final, binding and incontestable and may be used as a basis
for judgment thereon in the United States; the Republic of Indonesia or
elsewhere. All costs of arbitration in the appointment of the one (1)
member of the arbitration board shall be shared equally among the
parties.
(f) None of the parties herein shall be entitled to commence
or maintain any action in a court of law upon any matter in dispute
arising from or in relation to this Agreement except for the
enforcement of an arbitral award granted pursuant to this paragraph.
(g) During the period of submission to arbitration and
thereafter until the granting of the arbitral award, the parties shall,
except in the event of termination, continue to perform all their
obligations under this Agreement without prejudice to a final
adjustment in accordance with the said award.
(h) The parties expressly waive the Article 68 (b) of
Indonesian Law No. 30/1999 (Arbitration and Alternatives).
(i) The provisions contained herein shall survive the
termination and/or expiration of this Agreement.
12.15 WAIVER OF ARTICLE 1266 OF THE INDONESIAN CIVIL CODE For the
purposes of this Agreement the parties waive Article 1266 of the Indonesian Code
to the extent that judicial cancellation of this Agreement is required as a
precondition to terminate.
12.16 BOARD OF DIRECTORS OF ACUBID FOLLOWING THE CLOSING DATE AcuBid
agrees that at such times as it solicits proxies for the approval of this
Agreement by shareholders, it shall also solicit proxies for the election of a
Board of Directors consisting of eight persons, six (6) of whom shall be
designated by Seller and two (2) of whom shall be designated by management.
43
12.17 OTHER GOVERNMENT APPROVALS The Closing hereunder is subject to
receipt of all necessary government approvals and consents required to
consummate the transactions contemplated hereby including without limitation the
following:
(a) approval of BPM (Investment Board) on the conversion of
JDI to a PMA company subject to the Foreign Investment Law, as amended;
(b) approval of the Ministry of Laws and Legislation of the
amended Articles of Association of JDI reflecting the position of
AcuBid as a shareholder; and
(c) approval of the Minister of Communications (if required)
on the changes in shareholding structure of PT Medialintas Antarbuana
resulting from the AcuBid entry into JDI.
12.18 TERMINATION. The parties herein or any one of them may terminate
this Agreement for breach or if the Closing does not occur on or before August
31, 2000.
IN WITNESS WHEREOF, the parties hereto have duly executed this
Agreement as of the day and year first above written.
▇▇▇▇▇▇.▇▇▇ INC.
By: /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
-------------------------------------
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
PT JARING DATA INTERAKTIF
By: /s/ Jicky Iskansar di Nata
-------------------------------------
Jick Iskansar di Nata
ACUBID ACQUISITION CORP.
By: /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
-------------------------------------
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
SELLER:
/s/ Adisatrya suryo Sulisto
-------------------------------
Adisatrya Suryo Sulisto
WITNESSES:
1. 2.
3. 4.
44
THE JDI SCHEDULE
(A) Corporate Structure of PT Media Lintas Antarbuana
Authorized capital-Rupiah 2.800.000.00
Issued capital-Rupiah 700.000.000
Shareholders:
▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ 217 shares
PT Jaring Data Interactif 483 shares
Par value: Rupiah 1.000.000
(B) JDI Bank Acccounts
Bank Internasional Indonesia
Bank Central Asia
Bank Bukopin
Signatories: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ Dinata; ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇;
Agus Julianto; ▇▇▇▇▇ ▇▇▇▇▇▇▇.
(C) JDI Trademarks
Web ▇▇▇▇▇.▇▇▇ (now in process of registration)
Web 88888 (now in process of registration)
45